Investigational drug · Phase 2
DB-1324
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Gastrointestinal Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: May 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "DB-1324"
First trial start
2026
Jan 20, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DB-1324", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastrointestinal Cancer
Approved drugs for the same conditions: Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "DB-1324" as an intervention, largest first.
DualityBio Inc.Industry
NCT07263594 · 127 participants (planned) · Start Jan 20, 2026 · Primary completion Dec 2028
Drug: DB-1324 · For: Gastrointestinal Cancer
Sites: Port Saint Lucie, Florida; Grand Rapids, Michigan; Huntersville, North Carolina · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Gastrointestinal Cancer
- OH2Phase 36 trials
Binhui Biopharmaceutical Co., Ltd. · Melanoma, Solid Tumor, Gastrointestinal Cancer
- RMC-9805Phase 23 trials
Revolution Medicines, Inc. · PDAC, Colorectal Cancer, CRC
- CPT-11Phase 21 trial
Zhejiang Doer Biologics Co., Ltd. · Gastrointestinal Cancer
- DR30206Phase 21 trial
Zhejiang Doer Biologics Co., Ltd. · Gastrointestinal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.